Antibody therapies represent one of the most advanced disease-modifying approaches in neurodegenerative disease treatment. These therapeutics use monoclonal antibodies designed to bind specifically to pathological proteins—including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), and [alpha-synuclein](/proteins/alpha-synuclein)—marking them for immune clearance["@panza2019"]. The approval of [lecanemab](/entities/lecanemab) (Leqembi) in 2023 and [donanemab](/entities/donanemab) (Kisunla) in 2024 marked historic milestones as the first disease-modifying therapies for [Alzheimer's disease](/diseases/alzheimers-disease)[@van2023].
Mechanism of Action
Antibody therapeutics work through several complementary mechanisms:
Target Binding and Clearance
Soluble oligomer neutralization: Antibodies bind to toxic oligomeric forms of proteins before they can form plaques or tangles
Fc receptor-mediated phagocytosis: Antibody-coated targets are recognized by [microglia](/cell-types/microglia-neuroinflammation) and macrophages
Peripheral sink effect: Antibodies in blood may bind circulating protein, shifting equilibrium from the brain
Epitope Specificity
Different antibodies target different forms of the pathological proteins:
N-terminal antibodies: Bind early, aggregate-prone regions
Mid-domain antibodies: Target sequences involved in aggregation
C-terminal antibodies: Bind late-aggregation species
Conformational antibodies: Recognize specific aggregate conformations
Clinical Programs
Approved Therapies
Lecanemab (Leqembi)
Target: Amyloid-beta protofibrils
Manufacturer: Eisai/Biogen
Approval: FDA accelerated approval January 2023, full approval July 2023
Efficacy: 27% slowing of clinical decline in CLARITY-AD trial[@eisai2022]
Limitations: ARIA (amyloid-related imaging abnormalities) in 12.6% of patients
Donanemab (Kisunla)
Target: Amyloid-beta plaques
Manufacturer: Eli Lilly
Approval: FDA approval July 2024
Efficacy: 35% slowing in TRAILBLAZER-ALZ 2 trial
Limitations: ARIA in 24% of patients, requires regular imaging monitoring
Key Development Programs
Advantages
High Specificity
Antibodies offer exceptional target specificity:
Designed to bind single protein epitopes
Minimal off-target effects
Well-characterized pharmacology
Proven Efficacy
The approval of lecanemab and donanemab validates:
Amyloid removal correlates with clinical benefit
Disease modification is achievable
The amyloid hypothesis has clinical relevance
Established Manufacturing
Scalable biopharmaceutical production
Rigorous quality control standards
Extensive regulatory precedent
Limitations
High Cost
Annual treatment costs exceed $30,000
Additional costs for monitoring and administration
Long-term treatment may be required
Blood-Brain Barrier Penetration
Only 1-2% of peripheral antibodies reach the CNS
Requires high doses for effect
Limits efficacy ceiling
Amyloid-Related Imaging Abnormalities (ARIA)
Brain edema (ARIA-E): 10-15% of patients
Microhemorrhages (ARIA-H): 15-20% of patients
Requires MRI monitoring
More common in APOE4 carriers
Late-Stage Intervention
Clinical benefit limited to early disease stages
Significant plaque burden may limit reversibility
Biomarker screening required
Future Directions
Next-Generation Antibodies
Brain shuttle antibodies: Engineering to enhance CNS delivery
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄